Skip to content
The Kids Research Institute Australia logo
Donate

Search

Echocardiographic screening for rheumatic heart disease in high and low risk Australian children

We aimed to establish the prevalence of RHD in high-risk Indigenous Australian children using these criteria and to compare the findings with a group of...

Benzathine penicillin G for the management of RHD: Concerns about quality and access, and opportunities for intervention and improvement

Benzathine penicillin G is an important antibiotic for the treatment and prevention of group A streptococcal infections associated with rheumatic fever and...

A conceptual framework for comprehensive rheumatic heart disease control programs

The World Health Organization, World Heart Federation, and other organizations recommend comprehensive control programs for rheumatic fever (RF) and...

Prevention of rheumatic fever and heart disease: Nepalese experience

Historically, many young people suffered severe valvular disease and died awaiting heart valve replacement.

Continued challenge of rheumatic heart disease: The gap of understanding or the gap of implementation?

We still do not have a RF vaccine, although the recent announcement that the Australian and New Zealand governments are jointly sponsoring a program to fast...

Position statement of the World Heart Federation on the prevention and control of rheumatic heart disease

In the 21st century, rheumatic fever (RF) and rheumatic heart disease (RHD) are neglected diseases of marginalized communities.

Screening for rheumatic heart disease: current approaches and controversies

In endemic areas, RHD has long been a target of screening programmes that, historically, have relied on cardiac auscultation.

Acute Rheumatic Fever and Chronic Rheumatic Disease

This chapter describes the epidemiology, pathogenesis, clinical manifestations, diagnostic criteria, and management principles of acute rheumatic fever.

High dose, subcutaneous injections of benzathine penicillin G (SCIP) to prevent rheumatic fever: A single arm, phase IIa trial of safety and pharmacokinetics

This Phase-IIa trial evaluates the safety and pharmacokinetics of high-dose, 10 weekly subcutaneous injections of penicillin (SCIP) in young people with a history of acute rheumatic fever (ARF).

Establishing the lowest penicillin concentration to prevent pharyngitis due to Streptococcus pyogenes using a human challenge model (CHIPS)

The in-vivo plasma concentration of penicillin needed to prevent Streptococcus pyogenes pharyngitis, recurrent acute rheumatic fever, and progressive rheumatic heart disease is not known. We used a human challenge model to assess the minimum penicillin concentration required to prevent streptococcal pharyngitis.